JP2021523109A5 - - Google Patents

Info

Publication number
JP2021523109A5
JP2021523109A5 JP2020561057A JP2020561057A JP2021523109A5 JP 2021523109 A5 JP2021523109 A5 JP 2021523109A5 JP 2020561057 A JP2020561057 A JP 2020561057A JP 2020561057 A JP2020561057 A JP 2020561057A JP 2021523109 A5 JP2021523109 A5 JP 2021523109A5
Authority
JP
Japan
Prior art keywords
phenyl
alkyl
substituted
hydrogen
independently
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020561057A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021523109A (ja
JP7089062B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/030028 external-priority patent/WO2019213153A1/en
Publication of JP2021523109A publication Critical patent/JP2021523109A/ja
Publication of JP2021523109A5 publication Critical patent/JP2021523109A5/ja
Application granted granted Critical
Publication of JP7089062B2 publication Critical patent/JP7089062B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020561057A 2018-04-30 2019-04-30 老化細胞によって引き起こされるかまたは媒介される状態の臨床管理における使用のためおよびがんを治療するための、Ｂｃｌファミリーアンタゴニストであるホスホリジン Expired - Fee Related JP7089062B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201862664891P 2018-04-30 2018-04-30
US201862664863P 2018-04-30 2018-04-30
US201862664860P 2018-04-30 2018-04-30
US201862664850P 2018-04-30 2018-04-30
US62/664,850 2018-04-30
US62/664,860 2018-04-30
US62/664,891 2018-04-30
US62/664,863 2018-04-30
PCT/US2019/030028 WO2019213153A1 (en) 2018-04-30 2019-04-30 Phospholidines that are bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer

Publications (3)

Publication Number Publication Date
JP2021523109A JP2021523109A (ja) 2021-09-02
JP2021523109A5 true JP2021523109A5 (https=) 2022-04-20
JP7089062B2 JP7089062B2 (ja) 2022-06-21

Family

ID=66530472

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020560258A Active JP7080346B2 (ja) 2018-04-30 2019-04-30 老化細胞によって引き起こされるかまたは媒介される状態の臨床管理における使用のためおよびがんを治療するための、Ｂｃｌファミリーアンタゴニストであるホスホノアミダート
JP2020561053A Active JP7204780B2 (ja) 2018-04-30 2019-04-30 老化細胞によって引き起こされるかまたは媒介される状態の臨床管理における使用のためおよびがんを治療するための、Ｂｃｌファミリーアンタゴニストであるアシルホスホノアミダートおよびアシルベンジルアミン
JP2020561057A Expired - Fee Related JP7089062B2 (ja) 2018-04-30 2019-04-30 老化細胞によって引き起こされるかまたは媒介される状態の臨床管理における使用のためおよびがんを治療するための、Ｂｃｌファミリーアンタゴニストであるホスホリジン

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2020560258A Active JP7080346B2 (ja) 2018-04-30 2019-04-30 老化細胞によって引き起こされるかまたは媒介される状態の臨床管理における使用のためおよびがんを治療するための、Ｂｃｌファミリーアンタゴニストであるホスホノアミダート
JP2020561053A Active JP7204780B2 (ja) 2018-04-30 2019-04-30 老化細胞によって引き起こされるかまたは媒介される状態の臨床管理における使用のためおよびがんを治療するための、Ｂｃｌファミリーアンタゴニストであるアシルホスホノアミダートおよびアシルベンジルアミン

Country Status (5)

Country Link
US (1) US10703745B2 (https=)
EP (3) EP3788052A4 (https=)
JP (3) JP7080346B2 (https=)
CN (4) CN117866015A (https=)
WO (3) WO2019213160A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020140005A2 (en) 2018-12-29 2020-07-02 Newave Pharmaceutical Inc. Bcl-2 inhibitors
EP3906235B1 (en) 2019-01-04 2023-03-15 Ascentage Pharma (Suzhou) Co., Ltd. Method for preparing sulfonamides drugs
CN113248415B (zh) * 2021-05-26 2022-08-09 苏州正永生物医药有限公司 一种abt-737关键中间体的制备方法以及abt-737的制备方法
CN118717761A (zh) * 2024-05-27 2024-10-01 复旦大学 瑞美吉泮在制备治疗/预防阿尔茨海默病药物中的应用

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5807846A (en) 1996-11-14 1998-09-15 Warner-Lambert Company Phosphonamide ACAT inhibitors
MXPA01008937A (es) * 1999-03-05 2004-04-05 Metabasis Therapeutics Inc Nuevos profarmacos que contienen fosforo.
US7132427B2 (en) 2001-06-21 2006-11-07 Ariad Pharmaceuticals, Inc. Quinazolines and uses thereof
US7238679B2 (en) 2002-12-23 2007-07-03 Ariad Pharmaceuticals, Inc. Heterocycles and uses thereof
CA2600797A1 (en) * 2005-03-11 2006-09-21 The Regents Of The University Of Michigan Chromen-4-one inhibitors of anti-apoptotic bcl-2 family members and the uses thereof
US7834023B2 (en) * 2006-09-20 2010-11-16 Portola Pharmaceuticals, Inc. Substituted dihydroquinazolines as platelet ADP receptor inhibitors
US20080249130A1 (en) * 2007-02-09 2008-10-09 Sirtris Pharmaceuticals, Inc. Gut microsomal triglyceride transport protein inhibitors
US8124605B2 (en) * 2007-07-06 2012-02-28 Kinex Pharmaceuticals, Llc Compositions and methods for modulating a kinase cascade
US8563735B2 (en) 2008-12-05 2013-10-22 Abbvie Inc. Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
TWI535712B (zh) 2010-08-06 2016-06-01 阿斯特捷利康公司 化合物
CN103370326B (zh) 2010-12-16 2016-05-11 阿勒根公司 作为趋化因子受体调节剂的磷衍生物
EP2668180B1 (en) * 2011-01-25 2018-08-01 The Regents of The University of Michigan Bcl-2/bcl-xl inhibitors for use in the treatment of cancer
WO2012177927A1 (en) 2011-06-21 2012-12-27 Mayo Foundation For Medical Education And Research Transgenic animals capable of being induced to delete senescent cells
WO2013052943A2 (en) * 2011-10-06 2013-04-11 The Regents Of The University Of Michgian Small molecule inhibitors of mcl-1 and uses thereof
US9901080B2 (en) 2012-08-23 2018-02-27 Buck Institute For Research On Aging Transgenic mouse having a transgene that converts a prodrug into a cytotoxic compound in senescent cells
US20160038503A1 (en) 2012-11-21 2016-02-11 David Richard Methods and compositions useful for treating diseases involving bcl-2 family proteins with isoquinoline and quinoline derivatives
EP3689886A1 (en) * 2013-01-16 2020-08-05 The Regents of The University of Michigan Bcl-2/bcl-xl inhibitors and their use in the treatment of cancer
RU2015149680A (ru) 2013-04-21 2017-05-24 Йеда Ресеарч Энд Девелопмент Ко. Лтд. Агенты для подавления активности и/или снижения количества bcl-xl и/или bcl-w
US10328058B2 (en) * 2014-01-28 2019-06-25 Mayo Foundation For Medical Education And Research Treating atherosclerosis by removing senescent foam cell macrophages from atherosclerotic plaques
US20170216286A1 (en) 2014-01-28 2017-08-03 Mayo Foundation For Medical Education And Research Killing senescent cells and treating senescence-associated conditions using a src inhibitor and a flavonoid
IL286427B2 (en) 2014-01-28 2024-08-01 Mayo Found Medical Education & Res Inhibitors bcl-2 anti-apoptotic protein family members for treatment of non cancer pulmonary disease or an opthalmic disease
US10550190B2 (en) 2014-04-04 2020-02-04 Merck Sharp & Dohme Corp. Phosphate based linkers for intracellular delivery of drug conjugates
EP3139942B1 (en) 2014-05-05 2019-12-18 Bioventures, Llc COMPOSITIONS AND METHODS FOR INHIBITING ANTIAPOPTOTIC Bcl-2 PROTEINS AS ANTI-AGING AGENTS
US20180000816A1 (en) * 2015-02-06 2018-01-04 Unity Biotechnology, Inc. Use of a Heterocyclic Bcl-xL Inhibitor and Related Analogs for Removing Senescent Cells in the Treatment of Eye Diseases and Other Age-Related Conditions
WO2016127135A1 (en) * 2015-02-06 2016-08-11 Unity Biotechnology, Inc. Compounds and uses in treatment of senescence-associated conditons
US10195213B2 (en) 2015-03-13 2019-02-05 Unity Biotechnology, Inc. Chemical entities that kill senescent cells for use in treating age-related disease
US20180199575A1 (en) 2015-07-15 2018-07-19 Bayer Cropscience Aktiengesellschaft Substituted oxotetrahydroquinolinylphosphinic acid and phosphinic acid amides or salts thereof and use thereof to increase stress tolerance in plants
CN105646587B (zh) * 2016-03-02 2018-03-23 云南中医学院 1,3,2‑氧氮磷杂环戊烷类化合物、制备方法及应用
WO2019001171A1 (zh) 2017-06-27 2019-01-03 维眸生物科技上海有限公司 一种含磷化合物及其制备和应用
WO2019033122A1 (en) 2017-08-11 2019-02-14 Unity Biotechnology, Inc. TREATMENT OF PULMONARY DISEASES USING PHARMACEUTICAL AGENTS THAT ELIMINATE SENESCENT CELLS
WO2019033119A1 (en) 2017-08-11 2019-02-14 Unity Biotechnology, Inc. TREATMENT OF OPHTHALMIC CONDITIONS SUCH AS MACULAR DEGENERATION, GLAUCOMA AND DIABETIC RETINOPATHY USING PHARMACEUTICAL AGENTS THAT ELIMINATE SENESCENT CELLS

Similar Documents

Publication Publication Date Title
JP2021523109A5 (https=)
JP2021522270A5 (https=)
JP2022533398A5 (https=)
JP2021535104A5 (https=)
JP2007504160A5 (https=)
CA2796967A1 (en) Heterocyclic derivatives as alk inhibitors
JP2021502387A5 (https=)
JP2023545396A5 (https=)
HRP20180199T1 (hr) Urea derivati ili njihove farmakološki prihvatljive soli korisni kao agonisti formil peptidnom receptoru-sličnom i (fprl-1)
JP2014526500A5 (https=)
MX2013015370A (es) Terapia de combinacion que comprende un inhibidor de cdk4/6 y un inhibidor de pi3kpara usarse en el tratamiento de cancer.
EP1986643A1 (en) Treatment of duchenne muscular dystrophy
JP2008517926A5 (https=)
RU2012116877A (ru) Соединения 2-пиридона, применяемые в качестве ингибиторов нейтрофильной эластазы
JP2021523108A5 (https=)
JP2010538094A5 (https=)
JP2013531070A5 (https=)
JP2013542267A5 (https=)
JP2018522861A5 (https=)
JP2022535734A5 (https=)
RU2014107000A (ru) Производные 3-гетероароиламинопропионовой кислоты и их применение в качестве лекарственных средств
RU2004107261A (ru) Арилсульфонильные производные, обладающие сродством к рецептору 5-нт6
NO168476C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 4-(4-(4-(4-(((2,4-difluorfenyl)-2-(1h-azolylmetyl)-1,3-dioxolan-4-yl)metoksy)fenyl)-1-piperazinyl)fenyl)triazoloner.
JP2009541387A5 (https=)
JP7089062B2 (ja) 老化細胞によって引き起こされるかまたは媒介される状態の臨床管理における使用のためおよびがんを治療するための、Ｂｃｌファミリーアンタゴニストであるホスホリジン